低活度放射性碘治疗伴淋巴结转移和腺外侵犯的甲状腺癌可能导致早期复发
该研究纳入1995至2008年接受甲状腺切除术及放射性碘治疗的分化型甲状腺癌患者219例,随访至少5年。结果显示,同时存在腺外侵犯和淋巴结转移的患者接受<1850 MBq放射性碘治疗较>1850 MBq者无进展时间显著更短(25个月 vs 121个月,p=0.004)。低活度放射性碘与更多早期复发相关(p=0.003)。
要点
- 伴腺外侵犯和淋巴结转移者,低活度放射性碘的无进展时间显著短于高活度(25 vs 121个月)。
- 低活度放射性碘治疗与更多早期复发相关(p=0.003)。
- 无或仅一项不良病理特征者,无论初始活度,10年复发率<10%。
核心结论
- 在伴淋巴结转移和腺外侵犯的分化型甲状腺癌患者中,低活度放射性碘治疗者复发更常见,且复发多发生在初始治疗后四年内。
- 缺乏上述两项风险因素的患者接受低活度放射性碘(<1850 MBq)治疗预后良好,即使随访10年亦然。
研究设计与样本
- 纳入1995至2008年诊断为分化型甲状腺癌、接受甲状腺切除术及放射性碘治疗的患者219例,随访至少5年,采用标准化随访方案(生化和影像学评估复发)。
- 按初始放射性碘活度分层,采用Kaplan-Meier法计算无病生存率,log-rank检验定义显著性差异。
主要发现
- 队列中46%患者有临床转移,74%原发肿瘤>1.5 cm。
- 复发患者更常见腺外侵犯(p=0.002)和诊断时淋巴结转移(p<0.001)。
- 同时有腺外侵犯和淋巴结转移者,接受<1850 MBq放射性碘较>1850 MBq者进展时间显著更短(25个月 vs 121个月;p=0.004)。
- 使用较低活度放射性碘消融治疗与更多早期复发相关(p=0.003)。
- 年龄是否大于45岁或是否行6区清扫不影响复发时间;多因素分析中,诊断时淋巴结转移和多次应用放射性碘与复发风险增加相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The application of radioactive iodine in differentiated thyroid carcinomas has become more selective in an attempt to decrease morbidity. While ablative success has been documented, it is less clear how changes in radioactive iodine treatment strategies will influence long-term recurrence rates for patients with larger tumors and adverse pathological features, including extrathyroidal extension and nodal metastases. METHODS: Patients diagnosed between 1995 and 2008 with differentiated thyroid carcinoma treated with thyroidectomy followed by radioactive iodine treatment were eligible. All patients were followed for a minimum of five years using a standardized follow-up protocol requiring both biochemical and imaging assessments for recurrent disease (n = 219). Patients were stratified by initial radioactive iodine activity, and disease-free survival was calculated using the Kaplan-Meier method, with significant differences defined by the log-rank test. RESULTS: In this cohort, 46% of patients had clinical metastases and 74% had primary tumors >1.5 cm. Patients who had recurrences were more likely to present with extrathyroidal extension (p = 0.002) and lymph node metastases at diagnosis (p < 0.001). Patients presenting with both extrathyroidal extension and lymph node metastases had a significantly worse time to progression if treated with <1850 MBq radioactive iodine compared to those patients treated with >1850 MBq (25 months vs. 121 months; p = 0.004). The use of lower-activity radioactive iodine ablative therapy was associated with more early recurrences (p = 0.003). Being aged younger or older than 45 years did not impact the time to recurrence nor did the use of level 6 dissection. On multivariate analysis, lymph node metastases at diagnosis and multiple applications of radioactive iodine were linked to increased risk of recurrence. Patients with neither, or only one, adverse pathologic feature had excellent outcomes, regardless of initial ablative activity, with <10% of patients recurring over a 10-year time span. CONCLUSIONS: Recurrent disease in differentiated thyroid carcinoma is more common in patients treated with low-activity radioactive iodine in patients with lymph node metastases and extrathyroidal extension. These recurrences typically occur within four years of initial treatment. Patients lacking both of these risk factors treated with low radioactive iodine activity (<1850 MBq) have excellent outcomes, even after 10 years.
引用
- Chu KP, Baker S, Zenke J, et al. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence. Thyroid. 2018. PMID: 29742993. doi:10.1089/thy.2017.0136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。